Print this Page

Snapshot: Illumina (NASDAQ: ILMN)

Illumina
Name: Jay T. Flatley
Title: President and CEO
Company: Illumina, Inc.
Location: San Diego, CA
Illumina
Website: www.illumina.com
Social Media: @illumina
Year Founded: 1998
Number of Employees: 2,100
Description: Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Products or Pipeline, Phase: Systems include: HiSeq, MiSeq, BaseSpace, BeadXpress, Eco Real-Time PCR System, Genome Analyzer IIx, HiScanSQ and iScan
Applications include: Sequencing, Genotyping, SNP Genotyping & CNV Analysis, Gene Regulation & Epigenetic Analysis, Gene Expression Analysis, Protein Analysis, Real-Time PCR, Agrigenomics, Cytogenetics, Cancer Genomics and Microbiology

Why is innovation important to the life science industry?

Innovation is at the heart of the life sciences industry. If you look at a technology category such as next-generation sequencing – it has evolved even faster than the speed of computing over the last decade. At Illumina, we believe these types of innovations will move into the clinic quickly and ultimately transform healthcare.

What has been the most important advance in genomics in 2012?

The cost of sequencing has dramatically declined, and so has the time it takes to sequence a whole human genome, which Illumina’s HiSeq® 2500 can do in a single day. This is a remarkable achievement, considering that the Human Genome Project took 13 years and $2.7 billion to complete.

Why is genomics important for diagnostics?

Genomics is beginning to inform diagnosis and treatment for patients. This is particularly true for cancer, where whole genome sequencing is being used to identify variants that can drive disease progression, as well as to select therapies based on these findings. As we become better able to leverage genomic data in routine patient care, this will transform diagnostics as we know it today.

Permanent link to this article: http://www.californiabiomedreport.com/snapshot-illumina/